Tag: Empagliflozin

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

Coronary/Structural Heart by 0 comments

– In a new sub-analysis of the landmark EMPEROR-Preserved® Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 – Empagliflozin consistently improved outcomes across the full range of kidney function […]

Continue Reading →

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes

Coronary/Structural Heart by 0 comments

– Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitors – This analysis, which includes European data […]

Continue Reading →

Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

Coronary/Structural Heart by 0 comments

– In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease […]

Continue Reading →